CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Dasatinib 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01652976
NCT01652976Phase 2Completed
CompareCT.gov

Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib (FOLFOX-D) in First-line Metastatic Pancreatic Adenocarcinoma

University of Florida·interventional·Posted Jul 30, 2012·Updated Jan 5, 2021

In Brief

A Phase 2 clinical trial evaluating Dasatinib and mFOLFOX6 for Pancreatic Cancer Metastatic. Completed, enrolled 44 participants across 1 site.

Detailed Summary

The purpose of this research study is to determine if the study drug, dasatinib, given in combination with 5-Fluorouracil, leucovorin and oxaliplatin (FOLFOX) will work against metastatic pancreatic cancer. Dasatinib is a Food and Drug Administration (FDA) approved drug for treating chronic myelogenous leukemia and acute lymphoblastic leukemia, however it is not currently approved for use in the treatment of pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer Metastatic
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 30, 2012
Enrollment StartJul 1, 2012
Primary CompletionFeb 1, 2018
Study CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 13.9 years ago

Interventions

Dasatinibdrug

Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle

mFOLFOX6drug

mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle